Orexigen Therapeutics | Evaluate

Semaglutide repeats the obesity trick

August 28, 2018

Data point - How slimming down is growing up

March 14, 2018

Debt comes back to haunt biotech

March 07, 2018

Interview – Novo fattens up its obesity pipeline

July 20, 2016

The end of another chapter in obesity drug development

March 16, 2016

One way to save Valeant – stop being Valeant

November 11, 2015

A pyrrhic victory for Ocata investors

August 07, 2015

Orexigen trades one problem for another

May 13, 2015

Orexigen’s heavy price for Light miscalculation

March 04, 2015

Controversial disclosure will probably benefit Contrave in the long run

March 02, 2015

Contrave’s unexpected late turn in battle of the bulge

Load More